European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical’s Sickle Cell Treatment

July 17, 2012

TORRANCE, Calif., July 17, 2012 -- Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease. The EC designation follows the recommendation of the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products announced in May.